There appears to be movement in the US to bring less expensive versions of biotech drugs to market. But the brand name drug industry wants these so-called biosimilars to adhere to rigorous safety and efficacy standards currently not built into US laws. Tom DiLenge, vice president and general counsel for the Biotechnology Industry Organization, tells host Bruce Japsen about a palatable pathway biotech companies would like to see approved by Congress to bring cheaper biotech drugs to the US market.
What Biotech Companies Want in Generic Legislation
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
There appears to be movement in the US to bring less expensive versions of biotech drugs to market. But the brand name drug industry wants these so-called biosimilars to adhere to rigorous safety and efficacy standards currently not built into US laws. Tom DiLenge, vice president and general counsel for the Biotechnology Industry Organization, tells host Bruce Japsen about a palatable pathway biotech companies would like to see approved by Congress to bring cheaper biotech drugs to the US market.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
0.25 credits
<p>Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy</p>
CME/CE
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
1.00 credits
<p>Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
CME/CE
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
0.50 credits
<p>IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base</p>
CME/CE
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
0.50 credits
<p>IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement</p>
CME/CE
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
0.50 credits
<p>IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue</p>
MinuteCE®
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
1.00 credits
<p>Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?